Last $7.22 USD
Change Today +0.61 / 9.23%
Volume 11.4M
ARIA On Other Exchanges
As of 8:10 PM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).

ariad pharmaceuticals inc (ARIA) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/24/14 - $9.83
52 Week Low
10/13/14 - $4.90
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

ariad pharmaceuticals inc (ARIA) Related Businessweek News

No Related Businessweek News Found

ariad pharmaceuticals inc (ARIA) Details

ARIAD Pharmaceuticals, Inc., an oncology company, is engaged in the discovery, development, and commercialization of medicines for cancer patients. It offers Iclusig (ponatinib), a tyrosine kinase inhibitor for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia in the United States and Europe. The company is also developing Iclusig for other blood cancers and solid tumors, such as gastrointestinal stromal tumors, acute myeloid leukemia, and certain forms of non-small cell lung cancer; and various investigator-sponsored trials in indications, including first line and second line CML, acute myeloid leukemia, non-small cell lung cancer, and medullary thyroid cancer. In addition, its product pipeline consists of AP26113, an investigational inhibitor of anaplastic lymphoma kinase for treating advanced solid tumors comprising non-small cell lung cancer; and Ridaforolimus, an investigational mTOR inhibitor for various types of cancers. The company sells and markets Iclusig through specialty pharmacies and specialty distributors in the United States. It has collaboration and license agreement with Merck & Co., Inc. for the development, manufacture, and commercialization of ridaforolimus for use in cancer; and license agreements with Medinol Ltd. and ICON Medical Corp. to develop and commercialize stents and other medical devices to deliver ridaforolimus. ARIAD Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Cambridge, Massachusetts.

307 Employees
Last Reported Date: 03/3/14
Founded in 1991

ariad pharmaceuticals inc (ARIA) Top Compensated Officers

Principal Founder, Chairman, Chief Executive ...
Total Annual Compensation: $749.8K
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: $465.4K
President of Research & Development and Chief...
Total Annual Compensation: $492.4K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $679.0K
Chief Commercial Officer and Executive Vice P...
Total Annual Compensation: $427.3K
Compensation as of Fiscal Year 2013.

ariad pharmaceuticals inc (ARIA) Key Developments

Ariad Pharmaceuticals Inc. Announces Long-Term Safety and Efficacy Data of Ponatinib from Phase 2 Pace Clinical Trial

ARIAD Pharmaceuticals Inc. announced long-term follow up from its pivotal Phase 2 trial of Iclusig (ponatinib), its approved BCR-ABL inhibitor, in heavily pretreated patients with resistant or intolerant chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The study now shows that with a median follow-up of approximately 3 years for chronic-phase CML (CP-CML) patients in the trial, Iclusig continues to demonstrate anti-leukemic activity in patients with limited treatment options. Deep and durable responses have been maintained in CP-CML patients with 83 percent of CP-CML patients who achieved a response, estimated to remain in major cytogenetic response (MCyR) at three years. Additionally, the rate of maintenance of response in CP-CML patients was high (greater than 90%) in patients who underwent Iclusig dose reductions. Long-term safety data confirm that careful benefit-risk evaluations should guide the decision to use and then maintain Iclusig therapy, particularly in patients who may be at increased risk for arterial thrombotic events. PACE Trial Update: The efficacy and safety of ponatinib in CML and Ph+ ALL patients resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation, were evaluated in the pivotal Phase 2 PACE trial. A total of 449 patients were treated with ponatinib at a starting dose of 45 mg/day Ninety-three percent of patients treated in the PACE trial had failed two or more prior tyrosine kinase inhibitors (TKI), and 58 percent had failed three or more prior TKIs. Updated data in CP-CML patients (n=270) from the ongoing trial indicate that with a median follow-up of 38.4 months (data as of October 6, 2014), 121 patients (45%) continue to receive ponatinib. Additional data in CP-CML patients include: 55% of CP patients met the primary endpoint of MCyR by 12 months; 83% of patients who responded are estimated to remain in MCyR at 3 years; 39% of patients achieved a major molecular response (MMR) or better; By Kaplan-Meier analysis, progression-free survival at 3 years is estimated to be 61%; Overall survival at 3 years is estimated to be 82%; 22% of CP patients experienced an arterial thrombotic serious adverse event (SAE), and 27 percent of CP-CML patients experienced any arterial thrombotic event, independent of severity or attribution of relationship to ponatinib. There was no increase in the exposure-adjusted incidence of newly occurring arterial thrombotic events with longer follow-up; 4% of CP patients experienced a venous thrombotic SAE; The most common all-grade treatment-emergent adverse events in CP-CML were rash (46%), thrombocytopenia (45%), abdominal pain (45%), headache (43%), constipation (41%) and dry skin (41%); the discontinuation rate for adverse events was 17% in CP-CML.

Shire And AstraZeneca Mulls Acquisition Of Ariad

Shire plc (LSE:SHP) and AstraZeneca PLC (LSE:AZN) are rumored to acquire Ariad Pharmaceuticals Inc. (NasdaqGS:ARIA). Shire and AstraZeneca are stalking Ariad and an auction could ensue. Shares of Ariad closed at $7.38, Astra Zeneca at £46.74 and Shire at £45.63.

Ariad Pharmaceuticals Inc. and Specialised Therapeutics Australia Announce Approval of Iclusig(TM) (ponatinib) in Australia

Ariad Pharmaceuticals Inc. and Specialised Therapeutics Australia Pty Ltd. announce the marketing approval of Iclusig(TM) (ponatinib) in Australia by the Therapeutic Goods Administration (TGA). The Australian Product Information for Iclusig states that it is indicated for the treatment of adult patients with: Chronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (CML) whose disease is resistant to, or who are intolerant of at least two prior tyrosine kinase inhibitors; or where there is a T315I mutation; Philadelphia-chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) whose disease is resistant to, or who are intolerant of dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or where there is a T3151 mutation. Therapy should be initiated and monitored by a haematologist with expertise in managing adult leukaemias. ARIAD submitted its marketing application for Iclusig in the third quarter of 2013 to the Therapeutics Goods Administration (TGA), in Australia.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ARIA:US $7.22 USD +0.61

ARIA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Arena Pharmaceuticals Inc $3.99 USD -0.05
Array BioPharma Inc $4.86 USD +0.06
Infinity Pharmaceuticals Inc $17.73 USD +0.54
Pfizer Ltd/India 2,051 INR 0.00
Progenics Pharmaceuticals Inc $7.25 USD -0.095
View Industry Companies

Industry Analysis


Industry Average

Valuation ARIA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 26.3x
Price/Book 15.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 17.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ARIAD PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at